HLA-A*24疾患をコントロールした進行非小細胞肺癌に対するエピトープペプチドの安全性および有効性に関する研究

基本情報

NCT ID

NCT01950156

ステータス

完了

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

6

治験依頼者名

Shiga University

概要

The investigators previously identified three novel HLA-A\*2402-restricted epitope peptides, which were derived from three cancer-testis antigens, URLC10, CDCA1, and KIF20A, as targets for vaccination against lung cancer. In this clinical study, the investigators examine using a combination of these three peptides the safety, immunogenicity, and antitumor effect of vaccine treatment to prevent relapse of the disease for HLA-A\*2402-positive advanced non-small cell lung cancer patients whose disease are controlled after any standard therapies.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)